Drug intelligence / Profile preview

PF-07941314

Development stage: Phase 1
Lead developer: Pfizer
Modality: Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**PF-07941314** is Pfizer's investigational fixed-dose respiratory combination vaccine comprising an RSV protein-subunit vaccine component, RSVpreF, and a modified-RNA influenza vaccine component, qIRV. It was evaluated in the Phase 1 C5401001 study in older adults as 0.5 mL and 1.0 mL combined-vaccine formulations, assessing safety, tolerability, and immune responses against respiratory syncytial virus and influenza. Pfizer subsequently halted development of the early-stage RSV-influenza combination vaccine program. ([pfizer.com](https://www.pfizer.com/sites/default/files/plsr-studies/C5401001%20Plain%20Language%20Study%20Results%20Summary%20%28PLSRS%29%20Phase%201%20PK%20Primary%20Endpoint%20%28002%29.pdf))

Other names: RSV Subunit and Influenza modRNA Combination VaccineRSVpreF + qIRV

Beyond the preview

Go deeper on PF-07941314.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07941314.

Explore the full profile